(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 June 2008 (12.06.2008)

PCT

(10) International Publication Number
WO 2008/068475 A1

(51) International Patent Classification:
C07D 205/04 (2006.01) *A61P 7/02* (2006.01)
A61K 31/397 (2006.01)

(21) International Application Number:
PCT/GB2007/004640

(22) International Filing Date:
5 December 2007 (05.12.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/868,752 6 December 2006 (06.12.2006) US

(71) Applicant *(for all designated States except MG, US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant *(for MG only)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ÅSLUND, Bengt, Leonard** [SE/SE]; AstraZeneca R & D Södertalje, S-SE-151 85 Södertalje (SE). **BENGTSSON, Stefan** [SE/SE]; AstraZeneca R & D Södertalje, S-SE-151 85 Södertalje (SE). **BERGMAN, Gudrun, Anita** [SE/SE]; AstraZeneca R & D Södertalje, S-SE-151 85 Södertalje (SE). **HOHLNEICHER, Ursula, Renata, Maria** [DE/SE]; AstraZeneca R & D Mölndal, S-SE-431 83 Mölndal (SE). **YMÉN, Bo, Ingvar** [SE/SE]; AstraZeneca R & D Södertalje, S-SE-151 85 Södertalje (SE).


(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(54) Title: NEW CRYSTALLINE FORMS



(A)



(B)

(57) Abstract: There are provided crystalline forms of the compounds Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-Aze-Pab(OMe) (Compound A) and Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-Aze-Pab(OH) (Compound B), pharmaceutical compositions containing them, processes for obtaining them and their use in medical treatment.

WO 2008/068475 A1